IJGC conversations

• Surgical Approach in Recurrent Granulosa Cell Tumor with Tyler Hillman and Allison Lynn Brodsky

  In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Tyler Hillman and Allison Lynn Brodsky to discuss Surgical Approach in Recurrent Granulosa Cell Tumor.   Tyler Hillman, MD, PhD, is a board-certified gynecologic oncologist at UC San Diego Health, where he specializes in medical and surgical management of gynecologic cancers, with expertise in minimally invasive surgery, symptom management, and novel therapies. An associate professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences, he teaches medical students, residents, and fellows at UC San Diego School of Medicine. Dr. Hillman’s research focuses on rare ovarian cancers, particularly sex cord–stromal tumors, and he has published extensively in leading journals such as Nature, JNCI, and Gynecologic Oncology. He also holds leadership roles in NRG Oncology and the Society of Gynecologic Oncology. Allison Lynn Brodsky, MD, MS, is a fellow in gynecologic oncology at The University of Texas MD Anderson Cancer Center.  She completed her OBGYN residency at the University of California San Diego. Her research interests include rare gynecologic tumors, clinical trial development, and quality improvement. 

  --------  

  25:46

  --------

  25:46
• ctDNA: Results from CALLA Trial with Bradley Monk

  In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Bradley Monk to discuss ctDNA: Results from CALLA Trial.   Bradley Monk, MD, FACOG, FACS is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute and medical director of the Late-Stage Clinical Research Program. He provides care to patients at the FCS West Palm Beach location. Dr. Monk has extensive leadership experience in practice-changing clinical research and the development of clinical research programs in community oncology settings. His research special interests are primarily focused on the prevention and treatment of gynecologic cancers. As a principal investigator, Dr. Monk has been involved in numerous groundbreaking studies throughout his career. Dr. Monk is a co-founder of the GOG-Partners (GOG-P) Foundation® (GOG-F), a nonprofit organization committed to advancing clinical and scientific research in the field of gynecologic malignancies. The organization was instrumental in establishing a national gynecologic clinical trials network. He has presented his findings at hundreds of national and international forums and authored more than 400 peer-reviewed articles and more than 35 book chapters focused on the prevention and treatment of gynecologic malignancies and patient reported outcomes. Dr. Monk is a past recipient of the esteemed Ernst Wertheim Award for his research in cervical cancer. Prior to joining FCS in 2024, Dr. Monk served as director and principal investigator for HonorHealth at the Virginia G. Piper Cancer Center in Scottsdale, Arizona, where he also served as the site research leader for Sarah Cannon Research Institute. Among his numerous academic appointments, he most recently served as a professor on the Clinical Scholar Track at the University of Arizona College of Medicine.

  --------  

  36:54

  --------

  36:54
• ESGO/INCIP 2025 Guidelines for Cancer in Pregnancy with Frédéric Amant

  In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Frédéric Amant to discuss ESGO/INCIP 2025 Guidelines for Cancer in Pregnancy.   Frédéric Amant (MD, PhD) received his medical degree from the University of Leuven (KU Leuven), Belgium in 1992, completed his specialty training as an obstetrician/gynecologist in 1998 and his subspecialty training in gynecologic oncology in 2000. He defended his thesis on uterine sarcomas in 2002 at the KU Leuven. He is specialist at the UZ Leuven in Belgium. He is professor at the KU Leuven in Belgium and at the University of Amsterdam in the Netherlands, and honorary professor at the university of Pretoria, South Africa. Since 2024 he is council member of the European Society of Gynecologic Oncology. Frédéric Amant heads the Gynecologic Oncology research section at the University of Leuven, Belgium and at the Netherlands Cancer Institute. In 2005 he founded the “International Network on Cancer, Infertility and Pregnancy” (INCIP)(www.cancerinpregnancy.org), and chairs this network up till now. Since 2014, INCIP also registers young women who aim to preserve their fertility. In 2021 he launched the Advisory Board Cancer Infertility Pregnancy (ABCIP) under the umbrella of INCIP. In addition, Frédéric Amant founded Trace, the tumor xenograft platform at the KU Leuven and the Fund for Innovative Research at the KU Leuven. He co-founded ENITEC, the European Network on Individualized Treatment of Endometrial Cancer. Since 2024 he is member of the research council at the KU Leuven.

  --------  

  40:49

  --------

  40:49
• IJGC conversations 2025 August Editor's Choice

  In this episode of the IJGC conversations 2025 August Editor's Choice, Editorial Fellow Rim Abou Chakra and Mariana Carvalho Gouveia discusses the contents of the 2025 August issue of IJGC.   

  --------  

  19:01

  --------

  19:01
• IJGC EiC Summer Podcasts: HIPEC in Platinum-Sensitive Ovarian Cancer (HORSE Trial) with Anna Fagotti

  In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Anna Fagotti to discuss HIPEC in Platinum-Sensitive Ovarian Cancer (HORSE Trial). Anna Fagotti is a Professor and Consultant of Gynecologic Oncology at A. Gemelli University Hospital Foundation IRCCS. She is the President of ESGO - European Society of Gynaecological Oncology. Her research interests are Obstetrics and Gynecology, Gynecologic Oncology, Advanced Ovarian Cancer, Gynecological Cancer, and Laparoscopic Surgery.

  --------  

  31:11

  --------

  31:11

Mais podcasts de Saúde e fitness

Podcasts em tendência em Saúde e fitness

Sobre IJGC conversations